Their 12 month data on PUL2 (+1.8) is no better than their 6 month data. Atl1102 had a +2.9 vs the natural history control at 6 months which Anp presented at the last WMS. (Natural history is better than placebo in DMD clinical trials)
They have no myoset or MRI data. There other observations aren’t worth much.
They have a safety issue with the need to pre-dose with an antihistamine.
They are requiring a partner to fund their pivotal study in DMD.
As stated before J&J walked away from their Stem cell technology
Conclusion:
In other words.. Anp has no rivals and will be first to market..
Eap approval in the next day or two will send the sp into orbit…30c minimum.. building to $5 and beyond in a couple of years….( patent Sept submitted covering multiple indications)
Anp is the next Aussie CSL..$$$$$
Their 12 month data on PUL2 (+1.8) is no better than their 6...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
